SOPHiA GENETICS (NASDAQ:SOPH) Trading 10.5% Higher – Still a Buy?

SOPHiA GENETICS SA (NASDAQ:SOPH)’s share price was up 10.5% during trading on Tuesday . The company traded as high as $6.19 and last traded at $6.2890. 54,810 shares were traded during trading, a decline of 73% from the average session volume of 199,691 shares. The stock had previously closed at $5.69.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its fiscal 2026 revenue outlook to $94 million–$96 million, above the roughly $93.4 million analyst consensus. Management continues to target adjusted EBITDA breakeven by year-end, which could improve confidence in the company’s path toward profitability. 2026 revenue outlook article
• Positive Sentiment: The company entered a multi-year collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The agreement may expand SOPH’s customer base and create longer-term opportunities in oncology testing. AstraZeneca partnership article
• Positive Sentiment: HC Wainwright raised its price target from $12 to $14 and BTIG Research increased its target from $8 to $9; both firms maintained Buy ratings. These revisions suggest some analysts see substantial upside if SOPH delivers on its growth and profitability targets. Analyst price target updates
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu collectively sold 35,000 shares worth approximately $242,350. Because all three transactions were conducted under pre-arranged Rule 10b5-1 plans and represented relatively small reductions in ownership, the sales provide limited information about management’s current outlook.
• Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, worse than the $0.21 loss analysts expected. Although revenue of $23.31 million exceeded the $21.72 million consensus, the company remains deeply unprofitable, with a negative net margin and analysts projecting a full-year loss. The earnings miss likely contributed to selling pressure. Q2 2026 earnings call transcript

Wall Street Analysts Forecast Growth

SOPH has been the subject of several analyst reports. HC Wainwright upped their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, BTIG Research lifted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Stock Down 7.9%

The firm has a 50-day moving average of $5.54 and a two-hundred day moving average of $5.12. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $528.51 million, a PE ratio of -5.48 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 153.15%. The business had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. Equities research analysts predict that SOPHiA GENETICS SA will post -0.58 earnings per share for the current fiscal year.

Insider Activity at SOPHiA GENETICS

In other SOPHiA GENETICS news, CTO Abhimanyu Verma sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $6.95, for a total value of $34,750.00. Following the transaction, the chief technology officer owned 187,171 shares of the company’s stock, valued at $1,300,838.45. This represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 10,000 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $6.92, for a total transaction of $69,200.00. Following the completion of the transaction, the insider directly owned 600,887 shares in the company, valued at $4,158,138.04. The trade was a 1.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 256,092 shares of company stock valued at $1,492,420 in the last quarter. Corporate insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently made changes to their positions in the stock. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at approximately $49,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS during the third quarter worth $49,000. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth $50,000. Quadrature Capital Ltd acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.